ASCO 2020：11项中国研究入选口头简报，17项Poster简报

备受世界性新冠疫情影响，月初于5同月29日~6同月2日在芝加哥参加的美国医学物理学时会（ASCO）筹备时会议当年将首次以线上形式举办，这是在此之前最大规模的线上盛时会。现在，全体时会议的概述题目揭晓，共103个sessions，中的国共有11项数据分析表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

硫替尼或拉帕替尼加卡培他滨运用于HER2+冠心病乳腺肺癌（PHOEBE）：一项III期随机试验性。

交响乐：冠心病乳腺肺癌

著者：中的国医学科学院的医院徐兵河客座教授、马飞客座教授，武汉大学另有的医院胡夕春客座教授等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可开刀三阴性乳腺肺癌标准病人后卡培他滨维持节拍化疗的III期试验性（SYSUCC-001）。

交响乐：乳腺肺癌—发散/区域/常规病人

著者：南京大学防治中的心称王树森客座教授等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用冠心病脊髓的表型特征来预见脊髓脊液中的循环DNA检测的均值: 新物件对抗来由宿敌

交响乐：新物件彻底解决来由问题

著者：徐美芹 徐德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为后期肾细胞时会肺癌的梯队病人：一项全站标签、随机、多中的心II/III期试验性。

交响乐：食道肠道肺癌—食道冠状动脉、发挥作用和实为

著者：浙江大学毛脉的医院毕锋客座教授、程子华淮海的医院秦叔逵客座教授等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国后期肾肺癌病人阿帕替尼二线病人：一项随机、安慰剂印证、双盲III期数据分析

交响乐：食道肠道肺癌—食道冠状动脉、发挥作用和实为

著者：程子华淮海的医院秦叔逵客座教授、浙江大学毛脉的医院徐秋客座教授等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期发作性卵巢肺癌二次细胞时会减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

栏目：外科肺肺癌

著者：武汉大学另有中的山的医院臧荣余客座教授等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肺癌根治性子宫切除术后常规病人中的的序贯放化疗对比单独超声或实时放化疗（STARS数据分析）：一项随机、印证、全站标签的III期试验性。

全体时会议：外科肺肺癌

著者：南京大学防治中的心白云客座教授、刘继红客座教授等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比化疗运用于可切除的EGFR特异性的N1-N2期NSCLC-随机III期医学试验性的最终总体猎食数据分析。

栏目：心脏病—非小细胞时会发散-区域/小细胞时会/其他背部

著者：东莞人民的医院吴一龙客座教授等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR特异性寡转回非小细胞时会心脏病病人梯队乙酰激酶衍生物建立联系或不建立联系致力前线发散超声：III期全站标签医学随机试验性（SINDAS）的中的期结果（NCT02893332）。

栏目：心脏病-非小细胞时会转回

著者：四川省人民的医院曾铭客座教授等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性丧命-1（PD-1）的人源化IgG4单克隆抗体建立联系阿昔替尼运用于冠心病黏膜乳癌病人的Ib期数据分析的总猎食期和生物；也数据分析。

栏目：乳癌/皮肤肺癌

著者：南京大学的医院郭军、盛锡楠客座教授等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的相容性和结果：标准化CAR-T细胞时会首次体内试验性病人发作/难治性T细胞时会急性免疫球蛋白时会肺炎（r/r T-ALL）的相容性和。全体时会议：开发中的的病人新科技-免疫病人。著者：称王岂料等概述：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利抗肿瘤在后期冠状动脉楔形细胞时会肺癌病人中的的应用：一项随机的全站标签II期试验性（ORIENT-2）。全体时会议：食道肠道肺癌-食道冠状动脉肺癌、发挥作用肺癌和实为道肺癌著者：徐建明客座教授等概述：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T细胞时会对髓母细胞时会瘤的根除性病人全体时会议：中的枢神经系统著者：代红久、孙斌、杨东、徐晖、邵晶晶、魏佳、赵旭东概述：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复缺失病人中的的应用全体时会议：开发中的的病人学-免疫病人著者：沈琳客座教授等概述：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病人发作/难治性ACUTE免疫球蛋白时会肺炎/淋巴瘤的首例体内医学试验性全体时会议: 开发性病人学-免疫病人著者简介：张明志，杨林等概述：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度衍生物（T）建立联系应运用于后期虚拟瘤病人的Ib期数据分析全体时会议：发展性病人学--分子靶向类固醇和生物学著者：龚继芳，沈琳客座教授等概述：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin病人发作性或冠心病冠状动脉楔形细胞时会肺癌（ESCC）病人的II期数据分析。全体时会议：食道肠道肺癌-食道冠状动脉、发挥作用和实为道肺癌的数据分析著者：称王志过关斩将，徐玉红，称王德申，称王凤华，任超，谭琼 称王志过关斩将、徐玉红、称王德深、称王凤华、任超、谭琼概述：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体时会议：食道肠道肺癌-食道冠状动脉肺癌、发挥作用肺癌和实为管肺癌的二线病人著者：宋艳等概述：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体环状RNA分类器运用于初始活体时检测高等级肺癌的分泌物外体环状RNA分类器：一项多中的心的回顾性数据分析全体时会议：泌尿生殖系统肺肺癌---肺癌、睾丸肺癌和肺癌著者简介：Liaoyuan Li等概述：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散后期宫颈肺癌并发化疗后的常规化疗全体时会议: 外科肺肺癌著者简介： 徐珉珉等概述：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人病变髓性肺癌的连续性：基于ALTER01031试验性的数据分析。时会话：头颈部著者：天津市的医院高明客座教授概述：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、体积和年龄对安洛替尼病人后病人剧情的影响: ALTER01031的亚组数据分析全体时会议：头颈部著者：天津市的医院高明客座教授概述：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA数据分析预见I-IIIA期非小细胞时会心脏病（NSCLC）病人术后发作: GASTO1035和GASTO1018的结果全体时会议：心脏病-非小细胞时会发散-地方性/小细胞时会/小细胞时会/其他胸科肺肺癌著者：Si-Yu Wang等概述：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞时会心脏病（NSCLC）中的EGFR乙酰激酶衍生物的新型耐药程序全体时会议:心脏病-非小细胞时会冠心病心脏病著者简介：赵昕，金玲玲，满宇，欧真假，和黄，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧真假、和黄、薛武、杨绍、范敏概述：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性中的后期乳癌总猎食的替代终点全体时会议：乳癌/皮肤肺癌著者：聂润聪，袁书过关斩将，徐元芳，陈英波，周志伟 聂润聪、袁书过关斩将、徐元芳、陈英波、周志伟概述：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人发作或冠心病临床表现恶性骨病人的II期数据分析全体时会议： 肉瘤著者：唐丽娜，牛晓辉，称王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、称王振、蔡启庆、涂崇奇、范正福、杨瑶概述：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在后期肉瘤病人多线病人中的的相容性和。全体时会议：肉瘤著者：姚伟涛，孙家过关斩将，玑，称王欣，杜新辉，田志浩，牛晓颖 姚伟涛、孙家过关斩将、玑、称王鑫、杜鑫辉、田志超、牛晓英概述：11526剧照：414